{"id":"l-lv-dl-lv","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"L-LV works by competitively inhibiting leucine aminopeptidase, an enzyme involved in the breakdown of amino acids. This inhibition leads to an accumulation of leucine in the body, which has various effects on cellular metabolism and function.","oneSentence":"L-LV is a synthetic amino acid derivative that acts as a competitive inhibitor of the enzyme leucine aminopeptidase.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:12.017Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various cancers"}]},"trialDetails":[{"nctId":"NCT06282120","phase":"","title":"Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-01-01","conditions":"Metastatic Biliary Tract Cancer","enrollment":30},{"nctId":"NCT05793008","phase":"NA","title":"Characterization of priMary And sEcondary STress Related takOtsubo","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-03-30","conditions":"Takotsubo Cardiomyopathy, Sepsis-induced Cardiomyopathy","enrollment":60},{"nctId":"NCT02023593","phase":"PHASE2","title":"FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma","status":"COMPLETED","sponsor":"Yuhong Li","startDate":"2012-03","conditions":"Advanced Esophageal Carcinoma","enrollment":35},{"nctId":"NCT03524508","phase":"PHASE2","title":"Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer","status":"COMPLETED","sponsor":"Changhoon Yoo","startDate":"2018-09-04","conditions":"Metastatic Biliary Tract Cancer","enrollment":178},{"nctId":"NCT01996306","phase":"PHASE3","title":"A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC","status":"COMPLETED","sponsor":"Epidemiological and Clinical Research Information Network","startDate":"2013-12-02","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms","enrollment":650},{"nctId":"NCT03303495","phase":"PHASE3","title":"A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2011-11-14","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms","enrollment":280},{"nctId":"NCT02280070","phase":"PHASE2","title":"RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).","status":"UNKNOWN","sponsor":"Clinical Research Support Center Kyush","startDate":"2013-09","conditions":"Rectal Cancer","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Leucovorin"],"phase":"phase_3","status":"active","brandName":"l-LV (dl-LV)","genericName":"l-LV (dl-LV)","companyName":"Epidemiological and Clinical Research Information Network","companyId":"epidemiological-and-clinical-research-information-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L-LV is a synthetic amino acid derivative that acts as a competitive inhibitor of the enzyme leucine aminopeptidase. Used for Treatment of various cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}